Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.43 |
| ▸ | FURIN | P09958 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | NPY1R | P25929 | 3/20 | 0.39 |
| ▸ | NPY4R | P50391 | 3/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20512998 | 1.00 | HTT (0.45) | HTTSIRT2SIRT1FURINNPY5R | |
| SCHEMBL20513040 | 0.93 | HTT (0.44) | HTTSIRT2SIRT1FURINNPY5R | |
| SCHEMBL20513041 | 0.93 | HTT (0.44) | HTTSIRT2SIRT1FURINNPY5R | |
| SCHEMBL26223125 | 0.90 | FURIN (0.42) | HTTSIRT2SIRT1FURINNPY5R | |
| SCHEMBL21607790 | 0.90 | FURIN (0.42) | HTTSIRT2SIRT1FURINNPY5R | |
| SCHEMBL23355149 | 0.90 | CTSL (0.42) | HTTSIRT2SIRT1FURINNPY5R | |
| SCHEMBL14978855 | 0.90 | NMT2 (0.45) | FURINNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL15692124 | 0.90 | NMT2 (0.45) | FURINNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20839656 | 0.89 | NPY5R (0.42) | HTTFURINNPY5RNPY1RNPY4R | |
| SCHEMBL24270749 | 0.88 | FURIN (0.43) | HTTSIRT2SIRT1FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ALFASIGMA S.P.A. (IT) | 2021-05-06 | — | — | US | disclosed |
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ALFASIGMA S.P.A. (IT) | 2021-05-06 | — | — | US | disclosed |
| EP-3600444-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | Alfasigma S.p.A. (IT) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178060-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ALFASIGMA S.P.A. (IT) | 2018-10-04 | — | — | WO | disclosed |
| EP-3381474-A1 | HISTONE DEACETYLASE INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCS) AND USE IN THERAPY | Alfasigma S.p.A. (IT) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ERBB3, HDAC6, ERBB2 | HTT 685/4885SIRT2 209/4885SIRT1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.